Uncategorized

17 students visited JSC OlainFarm during “Ēnu diena”

on February 14, 2020

On 12 February, during the “Ēnu diena”, a career education initiative for students, JSC OlainFarm hosted 17 students who showed an in-depth interest about the pharmaceutical sector. Students representing 10 local schools took the opportunity to familiarise themselves with the everyday work of the Manufacturing Department, Technical Department, the Laboratory of finished dosage forms, Chromatography Centre, the Central Laboratory of the Factory, the Commercial Department and Human Resources Management specialists at JSC OlainFarm.

“I am pleased that students have the opportunity to get an in-depth knowledge of the professions they are interested in as part of their education. Thanks to all the colleagues who provided the opportunity for students! I am proud that we are able to inspire the young people in Latvia to link their future to caring for others’ health. Nowadays salary isn’t the only criterion for people seeking a place to work, especially for young people. Work environment and growth opportunities play a big role. Encouraging employee growth in a learning environment is one of the directions of development for JSC OlainFarm” says Jeroen Weites, Chairman of the Board of JSC OlainFarm.

Students in grades 9 – 12 from the Riga State Gymnasium No. 1, Riga State Gymnasium No. 2, Riga State Technical School No. 47, Riga Jugla Secondary School, Olaine Secondary School No. 1, Riga Pardaugava Elementary School, Riga Secondary School No. 63, RTU Olaine College of Technology and Lubana Secondary School observed the daily tasks of JSC OlainFarm experts, students got a chance to take a closer look at what a career in the pharmaceutical industry would entail.

The survey conducted by Junior Achievement Latvia on student future careers shows a significant increase in students’ interest in the medical and healthcare sectors – 17% of the respondents would like to work in healthcare ranking it as one of the TOP3 most popular career choices alongside with social studies, commercial science and jurisprudence (22%) as well as humanities and the arts (17%).

read more
17 students visited JSC OlainFarm during “Ēnu diena”

JSC OlainFarm introduces experimental technologies to manufacture new products

on February 12, 2020

The implementation and audit of the project “Introduction of experimental technology for manufacturing of new products at JSC OlainFarm” was successfully completed in January of this year. As part of the project launched in May, 2017, altogether 253 components of an experimental production line were delivered and installed. Their total value was EUR 6.4 mln, including EUR 2.2 mln financing from the European Regional Development Fund.

It is planned that the new experimental production line and its components will be used for research and development of production technologies to make new products – intermediates, active pharmaceutical ingredients, final dosage forms, as well as for production technology transfer, manufacturing of new products and quality control, including in production of a new antituberculosis medication.

“Manufacturing is an important pillar within OlainFarm. Bringing innovation to the manufacturing process is critical for OlainFarm to build a sustainable future with new products we anticipate to launch as part of our growth strategy. I am proud OlainFarm is cooperation with the World Health Organization in supplying our anti-tuberculosis medication to devel

oping countries in Asia and Africa to improving the quality of life and life expectancy of the local population,” says Jeroen Weites, Chairman of the Management Board of JSC OlainFarm.

Marina Vorobjova-Vaisla, Director of the Entrepreneurship and Innovation Department of the Central Finance and Contracting

Agency approvingly evaluates OlainFarm’s strategic approach to investing the European Union (EU) funds: “OlainFarm is a company with many years of experience and continuous development, which invests the EU funds strategically, strengthening international competitiveness. Promoting business innovation is one of the most important goals nationally being supported by EU funds – we are pleased that there are companies that can make these goals achievable through their activities.”

Currently under development is a generic anti-tuberculosis product – one of the new OlainFarm products. The anti-tuberculosis drug is being transferred from the laboratory to the manufacturing and scaling at the industrial installations. Successful processes could lead to commercialization of the product as early as 2023.

“OlainFarm has a historically established expertise in the development and manufacture of anti-tuberculosis drugs, and we are confident that our product will help people all around the world dealing with this illness,” emphasizes Jeroen Weitess, Chairman of the Management Board of OlainFarm.

JSC OlainFarm makes active use of the opportunities and support offered by the EU funds through investments in research, innovations and technologies. The support provided by the EU funds has positive effects on the operations of JSC OlainFarm.

JSC OlainFarm is one of the largest pharmaceutical companies in the Baltic states with more than 45 years of experience in production of medicines and chemical and pharmaceutical products. The basic principle of the company is to produce reliable and effective top-quality products for Latvia and the global market. JSC OlainFarm exports its products to more than 60 countries worldwide, including the Baltic states, Russia, other CIS countries, Europe, North America, Asia and Australia.

read more
JSC OlainFarm introduces experimental technologies to manufacture new products

Joint Stock Company “Olainfarm” January 24, 2020 Extraordinary Shareholders Meeting has not been held due to lack of quorum

on January 24, 2020

Today, 24 January, JSC Olainfarm Extraordinary Shareholders meeting which was convened at the request of the company’s largest shareholder, OLMAFARM Ltd, did not take place due to lack of quorum. The Shareholders registered for the JSC Olainfarm Extraordinary Shareholders meeting represented 2 978 701 shares in total with voting rights or 21.15% of the voting capital. As a result, the Extraordinary Shareholders meeting did not have the quorum required.

According to the articles of association of the company, the Shareholder meeting cannot be held if the specified number of shareholders with the rights to vote on the items covered on the agenda is not represented. In order for the Shareholders meeting to be valid, it must be held in accordance with the articles of association of the company. As publicly stated in September, the District Court of Zemgale upheld the request to temporarily deny OLMAFARM the right to vote in the Shareholders meetings of JSC Olainfarm until the dispute is resolved.

Due to Extraordinary Shareholders meetings becoming a regularity, the order of these meetings has been improved. The registration for the Shareholders meeting took place immediately upon entering the company building, avoiding the need for the Shareholders to have to register twice. In addition, employees’ daily agendas were not altered allowing them to use the only canteen on the premises of the company.

Additional information:
Jānis Dubrovskis
Investor Relations Advisor of JSC Olainfarm
Ph.: +371 29178878
janis.dubrovskis@olainfarm.com

read more
Joint Stock Company “Olainfarm” January 24, 2020 Extraordinary Shareholders Meeting has not been held due to lack of quorum

OLMAFARM Ltd. misinforms the public and ignores the court’s judgment

on January 27, 2020

Extraordinary Shareholders’ meeting of JSC Olainfarm, convened, in accordance with the law, on 24 January, 2020 at 11:00AM (in the premises of JSC Olainfarm, 5 Rupnicu Street, Olaine) did not take place due to a lack of quorum. The existing Supervisory Council and Management Board of JSC Olainfarm continues its work.

Today, 27 January, publicly made information that allegedly a new Supervisory Council has been elected and changes made to the Management board, distributed by Peteris Rubenis, chairman of the Management Board of OLMAFARM Ltd., contains false information and is considered misinformation. On 24 January, the only lawful meeting was convened at 11:00AM and did not take place due to a lack of quorum. It should be noted that the Management Board of JSC Olainfarm is responsible for the registration of shareholders and the number of shareholders with voting rights present, which was also done. The findings were communicated to the shareholders present, and the information was published on Nasdaq Riga and distributed to the media.

There was no quorum for the Extraordinary Shareholders’ meeting
Reminding that the extraordinary shareholders’ meeting did not have the quorum required since the meeting had registered shareholders representing 2 978 701 shares in total with voting rights or 21.15% of the voting capital.

A minority of shareholders cannot become a majority  
According to the articles of association of the company, the shareholder meeting cannot be held if the specified number of shareholders with the rights to vote on the items covered on the agenda is not represented. In order for the shareholders meeting to be valid, it must be held in accordance with the articles of association of the company. As publicly stated in September, the District Court of Zemgale upheld the request to temporarily deny OLMAFARM Ltd. the right to vote in the shareholders meetings of JSC Olainfarm until the dispute is resolved. This means that OLMAFARM Ltd. and Pēteris Rubenis, Chairman of the Board, have blatantly ignored this court ruling.

Additional information:
Jānis Dubrovskis
Investor Relations Advisor of JSC Olainfarm
Ph.: +371 29178878
Email: janis.dubrovskis@olainfarm.com

read more
OLMAFARM Ltd. misinforms the public and ignores the court’s judgment

An official of the Ministry of Justice is trying to interfere in the operation of AS Olainfarm

on January 29, 2020

There is reason to believe that OLMAFARM Ltd. deliberately violated the court ruled ban and voted in a false Extraordinary Shareholders’ meeting

JSC Olainfarm has a reason to suspect the interference of Laila Medina, Deputy State Secretary for Legal Affairs at the Ministry of Justice, in the operation of the company. This can be inferred from publicly disclosed information provided by OLMAFARM Ltd. that the Ministry of Justice has been involved in an attempt to influence a dispute between Valerijs Maligins’ heir and the shareholders of JSC Olainfarm. The official from the Ministry of Justice has issued a favorable opinion to a particular shareholder, OLMAFARM Ltd., which allows to influence the company operations and the work of institutions under the authority of the Ministry, such as the Register of Enterprises, with the purpose of making decisions that are favorable for themselves, while ignoring the rights and views of other shareholders

The above is also confirmed by the fact that the largest shareholder, OLMAFARM Ltd., which has been denied voting rights by the court, claims that the Ministry of Justice has assessed the circumstances of the dispute with the heirs of JSC Olainfarm, incl. pending civil proceedings. It has allowed the Ministry of Justice to conclude that the arguments of OLMAFARM Ltd. are justified, but the court’s decision, in the context of a dispute with the heirs of JSC Olainfarm, regarding the denial on the use of voting rights is questionable.

JSC Olainfarm has addressed these facts with official letters to both the Ministry of Justice and the Register of Enterprises.

The conclusion by the Ministry of Justice is considered to be a gross violation of the principle of the independence of the judiciary and interference with the work of the judiciary. At the same time, it is the exact opposite of the Ministry of Justice’s previous position of not intervening in disputes between the parties.

Although in its opinion, the Ministry of Justice does not refer directly to any particular case, in the view of JSC Olainfarm, it does analyze a specific case that is currently in the process of litigation. The above is also confirmed by the fact that the Financial and Capital Market Commission (FCMC) has approached the Ministry of Justice and asked it to provide an answer in connection with the shareholders’ meetings of JSC Olainfarm.

According to publicly available information distributed by Peteris Rubenis, Chairman of the Board of OLMAFARM Ltd., the opinion by the Ministry of Justice and the explanation by the FCMC of determining the quorum at JSC Olainfarm Shareholders’ meetings has served as the basis for holding the Shareholders’ meeting in a manner not according to the Commercial Law.

A fraudulent Shareholders’ meeting has been held

It is known that Martins Tambaks has submitted unlawful amendments of the Supervisory Council and the Management Board to the Register of Enterprises, claiming that the Extraordinary Shareholders’ meeting allegedly took place near the premises of 5 Rupnicu Street, Olaine, at 11:36AM. This meeting has not been convened by the Management Board in accordance with the regulatory enactments and thus, in the opinion of JSC Olainfarm, it cannot be considered as an Extraordinary Shareholders’ meeting. This allows JSC Olainfarm to conclude that false news and a forgery of an Extraordinary Shareholders’ meeting were submitted to the Register of Enterprises. It should be brought to attention that Articles 272 and 275 of the Criminal Law request liability for the distribution of false information to a public authority and the falsification of documents. It should be emphasized that on 24 January, the only legitimate Extraordinary Shareholders’ meeting of JSC Olainfarm was convened at 11:00AM and was not held due to a lack of quorum.

This unrecognizable meeting has not been convened and it is not clear which JSC Olainfarm shareholders took part in this fraudulent meeting. The Commercial Law and the Law on the Financial Instruments Market stipulate the exact procedure for convening and holding an Extraordinary Shareholders’ meeting. Such a meeting has not been convened by the Management Board of JSC Olainfarm in accordance with the regulatory enactments and thus cannot be considered as a legitimate JSC Olainfarm Extraordinary Shareholders’ meeting.

OLMAFARM Ltd. has violated the court prohibition

JSC Olainfarm has reason to believe that OLMAFARM Ltd. has deliberately violated the court prohibition and voted on all issues on the agenda during the fraudulent meeting. This reinforces the suspicion that these persons have attempted to obtain an unlawful result through formal legal means in order to take control of JSC Olainfarm. In addition, JSC Olainfarm believes that the company should ensure equal shareholder protection. Publicly available information indicates that some of JSC Olainfarm shareholders have already condemned this behavior as unfair and unlawful.

The procedure for convening Shareholders’ meetings has been clearly defined by the legislator, amongst other things providing the right to all shareholders to be notified of an Extraordinary Shareholder’s meeting. The rights of other shareholders to participate in the meeting and to exercise the rights of shareholders specified in regulatory enactments were denied due to the lack of compliance with the procedure of convening and holding of the meeting.

read more
An official of the Ministry of Justice is trying to interfere in the operation of AS Olainfarm

In November Group’s revenues increased by 14%, revenues for the full year to exceed target

on December 16, 2019

JSC Olainfarm preliminary consolidated results for November 2019 indicate that revenues increased by 14% compared to the same month last year and reached 12.4 million euro. At the same time consolidated results for the first eleven months of 2019 show that revenues reached 131.2 million euro, which is an increase by 17%, compared to the eleven-month period of 2018. Extraordinary rapid increase in sales was in Kirgizstan, Kazakhstan and Russian markets. Products of Olainfarm Group during this period were sold in 55 markets worldwide.

Consolidated sales in November show revenue increase in eight out of ten main markets. In Russia sales grew by 34%, in Belarus by 15%, in Ukraine by 2%, in Kazakhstan by 47%, in Moldova by 27%, in Kirgizstan by 335%. The sales resumed in Italy, where there were almost no sales a year before. Drop in sales was recorded in Latvia by 3% and in Uzbekistan by 19%.

Extra sales to pharmaceutical distributors in Russia continued also in November. It is important to notice that these revenues are achieved under commercial terms, which are customary to normal market practice and do not affect profitability.

In the eleven months of 2019 Olainfarm Group’s revenues were 131.2 million EUR that is 17% more than a year before. Contribution of the main sales markets of Olainfarm Group increased to 80% of the total revenue – Russia had the largest share of 34%, Latvia – 27%, Belarus – 11% and Ukraine – 8%. The Group’s other major sales markets include Kazakhstan, Uzbekistan, the Netherlands, Germany, Tajikistan and Lithuania. The most rapid sales growth during this eleven-month period was achieved in the Netherlands, where sales grew by 161% compared to the last year, and in Uzbekistan where sales grew by 33%. Sales in Russia improved by 30%, in Latvia and Belarus by 11% and in Kazakhstan by 15%, in Germany by 2% and in Tajikistan by 30%. Amongst the largest sales outlets a decline was marked in Ukraine (-1%) and in Lithuania (-21%).

Total sales forecasted for Olainfarm Group this year are in the amount of 133.3 million EUR, and it is fulfilled by 98%. Although December revenues will be lower than the last year’s results, nevertheless annual sales figure will exceed the result of 2018.

“With the approach of the end of this year, JSC Olainfarm Group’s forecasted turnover plan has been almost completed. The good results of this year allow us to look at the upcoming year with optimism. Additional sales to Russian drug distributors are continuing in November related to the application of the requirements regarding verification of medicinal products in Russia starting next year. Sales in this market are expected to be lower in the first months of the upcoming year. Next year, the main challenges for Olainfarm will be related to the changes in the regulation of the Eurasian Union drug market, the renewal of drug files according to markets, the increase of internal process efficiency as well as the implementation of a new strategy,” emphasizes Lauris Macijevskis, Member of the Management Board of JSC Olainfarm.

November 2019, consolidated sales      Sales, thous. EUR    Share in total sales     Changes to November 2018
Russia4 64237%34%
Latvia3 19126%-3%
Ukraine1 33111%2%
Belarus1 0048%15%
Kazakhstan4293%47%
Croatia2162%N/A
Moldova1761%27%
Uzbekistan1581%-19%
Italy1501%16532%
Kirgizstan1411%335%
Other9688%-28%
Total12 407100%14%

 

11 months 2019, consolidated sales     Sales, thous. EUR      Share in total sales      Changes to 11 months 2018
Russia43 96434%30%
Latvia35 21527%11%
Belarus14 78811%11%
Ukraine10 5458%-1%
Kazakhstan3 5163%15%
Uzbekistan2 9622%33%
Netherlands2 0302%161%
Germany1 8081%2%
Tajikistan1 6901%30%
Lithuania1 3461%-21%
Other13 36510%10%
Total131 228100%17%

Unconsolidated sales – November and 11 months

According to preliminary unconsolidated figures, JSC Olainfarm sales reached 9.5 million euros in November, which represents an increase by 19% compared to November, 2018. Sale of products improved in Russia (+44%), Ukraine (+7%), Latvia (+3%), Belarus (+12%), Kazakhstan (+29%). The sales resumed in Italy and chemical substances in the amount of 216 thousand EUR were delivered to Croatia. The sales in November declined in Latvia by 9%, Uzbekistan by 19% and in Germany by 15%.

The unconsolidated sales results for the first eleven months of 2019 show that JSC Olainfarm sales reached 101.3 million euros, which represents an increase by 19% compared to the first ten months of 2018. During this reporting period, sales have increased in nine out of the ten major markets of Olainfarm – Russia (+40%), Latvia (+2%), Belarus (+9%), Uzbekistan (+33%), Kazakhstan (+2%), the Netherlands (+165%), Germany (+5%), Tajikistan (+27%) and in Italy (+69%). Revenues declined by 1% in Ukraine.

November 2019, unconsolidated sales     Sales, thous. EUR     Share in total sales     Changes to November 2018
Russia4 35446%49%
Latvia1 46715%-9%
Ukraine1 33114%7%
Belarus7007%12%
Croatia2162%NA
Uzbekistan1582%-19%
Kazakhstan1542%29%
Italy1502%16532%
Germany1351%-15%
Kirgizstan1181%266%
Other7228%-33%
Total9 505100%19%

 

Eleven months 2019 unconsolidated sales     Sales, thous. EUR      Share in total sales     Changes to eleven months 2018
Russia40 71740%40%
Latvia16 01316%2%
Belarus11 90312%9%
Ukraine10 27610%-1%
Uzbekistan2 9623%33%
Kazakhstan2 0382%2%
The Netherlands2 0522%165%
Germany1 8462%5%
Tajikistan1 6132%27%
Italy1 3151%69%
Other11 03511%6%
Total101 770100%19%

Results of subsidiaries – November and the first eleven months of 2019

The pharmacy chain SIA Latvijas Aptieka sales reached 2.3 million euros in November 2019, which represents a 7% increase compared to November 2018. 68 pharmacies were operating during this period. SIA Silvanols sales reached 0.6 million euros in November 2019, representing an increase by 17% vs. November 2018. The combined sales of Tonus Elast and Elast Medical in November 2019 were 0.8 million euros, which is by 26% less than this time last year. Olainmed and Diamed Medical Center sales reached 0.3 million euros, while the Belarus subsidiary NPK Biotest reached 0.3 million euros in sales in October that is higher by 31% than in November last year.

During the first eleven month period of 2019, SIA Latvijas Aptieka sales amounted to 23.8 million euros, demonstrating an 9% increase in comparison to the same time period last year. Sales of SIA Silvanols reached 5.4 million euros which is 1% less than last year. The combined sales of Tonus Elast and Elast Medical during eleven months this year totaled 8.8 million euros, which is a drop by 4%. Medical Centers Diamed and Olainmed revenues were 2.9 million euros during the first ten months of this year and the Belarus company NPK Biotest sales were worth 2.9 million euros, improving the result of the last year by 34%.

November 2019      11 months 2019
Sales markets of Olainfarm2946
Sales markets of the Group3755
Number of pharmacies68
Sales of Latvijas Aptieka, thous. EUR2 27123 841
Sales of Medical centers, thous. EUR2632 875
Sales of NPK Biotest, thous. EUR3042 864
Sales of Tonus Elast and Elast Medical, thous. EUR7808 842
Sales of Silvanols, thous. EUR6045 431

According to the JSC Olainfarm budget, unconsolidated sales are planned to reach 99 million euros in 2019, while consolidated sales are expected at 133 million euros.  According to these preliminary sales figures, in the first eleven months of 2019, 103% of annual target for unconsolidated sales and 98% of annual target for consolidated sales have been reached.

JSC Olainfarm is one of the biggest pharmaceutical companies in Latvia with more than 45 years of experience in production of medication and chemical and pharmaceutical products. A basic principle of company’s operations is to produce reliable and effective top -quality products for Latvia and the rest of the world. Products made by the Group are being exported to more than 60 countries of the world, including the Baltics, Russia, other CIS, Europe, Asia, North America and Australia.

Additional information:   
Jānis Dubrovskis
Investor Relations Advisor of JSC Olainfarm
Phone: +371 29178878
Email: janis.dubrovskis@olainfarm.com

read more
In November Group’s revenues increased by 14%, revenues for the full year to exceed target

JSC Olainfarm draws attention of the FCMC about Pēteris Rubenis’ false and tendentious statements

on December 10, 2019

JSC Olainfarm draws the attention of the Financial and Capital Market Commission (FCMC) to the fact that on December 5, 2019 Pēteris Rubenis, in the name of its largest shareholder limited liability company OLMAFARM, disseminated false and tendentious information about Olainfarm Supervisory Council electing new officers on the Management Board of the company. Olainfarm has asked the FCMC to assess the legality of Pēteris Rubenis’ actions of disseminating false information about Olainfarm’s governing bodies, their representatives and newly elected Management Board members to the public.

In Olainfarm’s view, Pēteris Rubenis deliberately distributes information that is negative, false and based on subjective assumptions on the behalf of its largest shareholder limited liability company OLMAFARM. As is well known, one of the factors influencing the price of a company’s share is public information about the company’s management and operations. Thus, the allegations made by Pēteris Rubenis, Chairman of the Management Board of OLMAFARM, whose election has been declared invalid by the court, adversely affect both the activities of Olainfarm and the possibility that it may violate the rights of other Olainfarm shareholders and cause damage to the Latvian capital market reputation.

On December 5, 2019, shortly after Elena Bushberg was elected as a member of the Management Board of Olainfarm, it was publicly announced that the largest shareholder of JSC Olainfarm OLMAFARM, represented by its Chairman of the Management Board Pēteris Rubenis, considered the appointment of these people for the Olainfarm Management Board as illegal. According to Clause 1, Paragraph 1 of Article 292 of the Commercial Law, one of the tasks of the Supervisory Council shall be to elect members of the Management Board and supervise the activities of the Management Board. Article 4 of the Articles of Association of Olainfarm stipulates that the Management Board shall consist of seven members. Until this day, the Management Board of Olainfarm has been operating with five members. By appointing Jeroen Weites as Chairman of the Management Board and electing E. Bushberg as a Member of the Management Board, Olainfarm has met all the requirements stated in the Commercial Law and the Financial Instruments Market Act.

Olainfarm cannot agree with the statement made by Pēteris Rubenis, on behalf of limited liability company OLMAFARM, as on August 14, 2019, information about Olainfarm’s intention to attract senior management with international experience in pharmacy was already published on the website of JSC Nasdaq Riga. According to that statement, amongst other things, it was planned to strengthen the management team of Olainfarm, the Supervisory Council of the company has decided to appoint a new candidate for the position of the Chairman of the Management board with international experience in pharmacy. The change of the Chairman of the Management board is a planned strategic decision in the direction of development of Olainfarm in order to facilitate the acquisition of new markets and increase the international competitiveness of the company. Given that Pēteris Rubenis publicly commented the announcement on August 15, 2019, there is no reason to believe that he was not aware of the intention of Olainfarm’s Supervisory Council to advance the operation of the company as well as the process of selecting candidates.

Attention should also be drawn to the fact that J. Weites and E. Bushberg were selected in the framework of an international recruitment tender provided by an independent international top-level recruitment company – Amrop Latvija. During the selection process, the eligibility of the candidates for the Olainfarm Management Board member position has been carefully assessed and no circumstances have been identified that would prevent them from holding the position of the Chairman and Member of the Management Board.

It should be noted that by the ruling of the Zemgale District Court on November 20, 2019, the court has annulled the decision made during the meeting of the shareholders of limited liability company OLMAFARM on June 13, 2019, appointing its sole member Pēteris Rubenis as a member of the Management Board and demoting the previous Management Board member.

JSC Olainfarm is one of the largest companies in the Baltic States with more than 45 years of experience in production of pharmaceuticals and chemical and pharmaceutical products. The basic principle of the company is to produce reliable and effective top quality products for Latvia and the whole world. Currently, JSC Olainfarm products are exported to more than 60 countries worldwide, including the Baltic States, Russia, other CIS countries, Europe, North America, Asia and Australia.

Additional information:   
Jānis Dubrovskis
Investor Relations Advisor of JSC Olainfarm
Phone: +371 29178878
Email: janis.dubrovskis@olainfarm.com

read more
JSC Olainfarm draws attention of the FCMC about Pēteris Rubenis’ false and tendentious statements

Olainfarm Group announced the appointment of a new executive

on December 5, 2019

Today, the Supervisory Council of JSC Olainfarm approved Elena Bushberg as a member of the Management Board and CEO of Olainfarm, a part of Olainfarm Group of companies. Elena Bushberg brings over 25 years of international pharmaceutical experience to the Management Board in areas such as finance, supply & operations, marketing and sales in CIS countries, with engagement in creating, managing, and leading high performing teams and developing talent across multiple business areas.

In order for the company to achieve its future strategic goals, JSC Olainfarm Supervisory Council has improved the distribution of corporate governance functions: 1) the Chairman of the Management Board of JSC Olainfarm monitors the corporate governance of the Olainfarm Group of companies; 2) a member of the Olainfarm Management Board acts as the CEO of the largest enterprise of the Group JSC Olainfarm.

Last week Jeroen Waites was approved as the Chairman of the Management Board and CEO of the Olainfarm Group of companies and he is entrusted with the overall management and strategic development of the Olainfarm Group of companies as well as new market niche and sales market expansion. The Olainfarm Group of companies includes Olainfarm, Latvijas aptieka, Silvanols, Tonus Elast, DiaMed, OlainMed, NPK Biotest and Kiwi Cosmetics.

In addition, Elena Bushberg has been appointed as a member of the Management Board and CEO of JSC Olainfarm, the main business entity in the Olainfarm Group of companies, her primary focus will include leading the transformation of business processes at JSC Olainfarm and its existing affiliates to raise productivity and effectiveness of manufacturing, as well as sales and marketing operations in order to achieve sustainable organic growth ahead of the curve.

Chairman of the Supervisory Council of JSC Olainfarm Gundars Bērziņš emphasizes: “We have succeeded in fusing two competencies that are very important for the company – knowledge of pharmaceutical business in both the European Union and CIS markets, which will provide the company with the necessary additional capacity for development. We are proud to have such experienced professionals join the Olainfarm team. During the senior management selection process, we highly valued Elena Bushberg’s global view on the development of the pharmaceutical industry, marketing experience, knowledge of the specifics of the CIS markets, and expertise in managing operations and building strong sales teams. ”

Elena Bushberg, a member of the Board and CEO of JSC Olainfarm: “Olainfarm is a strong international brand, well respected not only in Latvia but also worldwide, especially in the markets I have specialized in. I am excited to join JSC Olainfarm in order to bring fresh and insightful industry perspectives as well as deliver added value to the company. JSC Olainfarm has a lot of untapped business potential and the grounds for  becoming a true Baltic pharmaceutical champion. I am honored to be a part of the leadership team creating the next chapter in the JSC Olainfarm success story.

Elena Bushberg’s professional experience adds up to over 25 years at international pharmaceutical companies such as Schering-Plough, MSD and Abbott Laboratories. Since 2015 E. Bushberg has served as the General Manager of Abbott’s Veropharm, one of Russia’s leading manufacturers of pharmaceuticals and medical devices. While in this position (during the time period of 2015-2019) E. Bushberg was responsible for developing and implementing the corporate strategy, leading organizational transformation and building a winning mind-set and culture in order to raise the efficiency of business operations, thus delivering sustainable organic and inorganic growth in sales and profits. Elena Bushberg holds a professional master’s degree (Global Executive MBA) and a Certificate in Healthcare Sector Management from The Fuqua School of Business, Duke University, USA.

Elena Bushberg does not own any shares at JSC Olainfarm or any other companies. E. Bushberg will start her actual employment at the company as soon as she has received the necessary formalities for employment in Latvia.

Jeroen Weites, Lauris Macijevskis, Raimonds Terentjevs, Signe Baldere-Sildedze, Milana Beļeviča and Mārtiņš Puriņš remain on the Management Board of the JSC Olainfarm.

JSC Olainfarm is one of the largest companies in the Baltic States with more than 45 years of experience in production of pharmaceuticals and chemical and pharmaceutical products. The basic principle of the company is to produce reliable and effective top quality products for Latvia and the whole world. Currently, JSC Olainfarm products are exported to more than 60 countries worldwide, including the Baltic States, Russia, other CIS countries, Europe, North America, Asia and Australia.

Additional information:  
Jānis Dubrovskis
Investor Relations Advisor of JSC Olainfarm
Phone: +371 29178878
Email: janis.dubrovskis@olainfarm.com

read more
Olainfarm Group announced the appointment of a new executive

Groups 9 months profit increased by 158% and exceeds 19 million EUR; active work has begun on renewal of drug dossiers

on November 29, 2019
  • During the first nine months of this year Group’s sales reached 98 774 thousand EUR, which is an increase by 10%.
  • Group’s EBITDA was 26 257 thousand EUR, which is by 83% higher.
  • Group’s profit reached 19 198 thousand EUR, which is the largest profit amount in history.

“Over the last nine months, we have been able to increase the Olainfarm Group’s profits to the highest level historically. This year, we have established a sufficiently stable financial base to further invest in the development of the company. Essentially it is planned to invest in the renewal of drug files so that we could continue to distribute our pharmaceutical products in the existing markets,” explained Lauris Macijevskis, Member of the Managing Board of JSC Olainfarm.

Group’s sales during the 3rd quarter of 2019 were 32 382 thousand EUR and that is by 17% more than in the 3rd quarter of 2018 when sales were 27 661 thousand EUR. In the 3rd quarter EBITDA was 9 329 thousand EUR that surpassed the figure of the 3rd quarter of 2018 by 5 339 thousand EUR or 134%. Profit for this year’s third quarter was 6 954 thousand EUR, which is an increase by 317% or 5 286 thousand EUR in comparison with the third quarter of 2018.

During the first nine months of this year Group’s sales reached 98 774 thousand EUR, which is an increase by 10% or 9 269 thousand EUR comparing to the same period of 2018. Group’s EBITDA figure during this year’s first nine months was 26 257 thousand EUR, which is by 83% or 11 928 thousand EUR more than the nine months results of the last year. Group’s reporting period profit for the nine months 2019 was 19 198 thousand EUR, which is the largest profit amount in history. Profit increased by 158% or 11 744 thousand EUR in comparison with the same period in 2018.

The reporting period profit was favorably affected by increase in gross profit by 6 624 thousand EUR, decrease in selling expense by 4 359 thousand EUR, income from foreign exchange fluctuations (2 038 thousand EUR) against losses of 1 479 thousand EUR from foreign exchange fluctuations in the nine months 2018 but was negatively affected by increase in administrative expenses.

In accordance with the approved plans Group’s sales target is fulfilled by 74% and profit figure by 151%.

As at 30 September 2019 Group has accumulated 11.4 million EUR in cash, which serves as one of the financing sources for investments in intangible assets for renewal of dossiers of all the major drugs as well as to continue investments in equipment. Group plans to continue to keep high free cash level.

Group’s main markets during the first nine months of this year are Latvia, Russia, Belarus and Ukraine, where total share is 78% of sales, which is a decline by two percentage points in comparison to the same period of the last year. All the main sales markets recorded increase except for Ukraine where decline in revenues for the three quarters this year is negligible. Group’s management is actively working to diversify sales channels by seeking beneficial cooperation partners with relevant experience and ability to advance Group’s products in markets.

During the first nine months of this year sales volumes of the main Olainfarm final dosage forms continued to increase. The share of the leading product Noofen increased to 20%, which is by one percentage point more than a year before. The share of the three largest products comprise 55% that is the same as the  year before.

At the same time in the 3rd quarter this year the best-selling product was Neiromidin with 22% share, followed by Noofen with 20% and Furamag/Furasol group with 18%.

In relation to renewal of drug dossiers Group has attracted a US based international pharma and healthcare consultancy company which reviews all major products and markets. Research results will allow Group to prepare strategy for further development and to make more precise estimates of required investment amounts and research terms.

During the third quarter of 2019, more than 565 thousand shares of JSC Olainfarm, with total value of 3.8 million euros, were traded on Nasdaq Riga. Compared to the same period in 2018, the number of traded shares was higher by 135% more, while traded value was higher by 127%. During the first nine months of this year there were 5 024 trades with 1 453 910 shares for the total value of 9.4 million EUR.

Condensed Consolidated Statement of  Financial Position

Group
30.09.2019      31.12.2018
EUR ‘000EUR ‘000
  ASSETS
NON-CURRENT ASSETS
Intangible assets  36 550  36 619
Property, plant and equipment  44 417  43 697
Right-of-use assets  7 467  –
Investment properties  3 469  3 492
Other non-current assets  855  983
TOTAL NON-CURRENT ASSETS  92 758  84 791
CURRENT ASSETS
Inventories  28 682  25 794
Receivables  32 092  34 637
Cash  11 437  2 689
TOTAL CURRENT ASSETS  72 211  63 120
TOTAL ASSETS  164 969  147 911
  EQUITY AND LIABILITIES
EQUITY
Share capital  19 719  19 719
Share premium  2 504  2 504
Reserves  47  (224)
Retained earnings  100 868  83 079
TOTAL EQUITY  123 138  105 078
LIABILITIES
Non-current liabilities
Borrowings and lease liabilities  13 283  1 793
Deferred income  3 089  2 878
Total Non-Current Liabilities  16 372  4 671
Current liabilities
Borrowings and lease liabilities  10 565  23 236
Trade payables and other liabilities  14 305  14 540
Deferred income  589  386
Total Current Liabilities  25 459  38 162
TOTAL LIABILITIES  41 831  42 833
TOTAL EQUITY AND LIABILITIES  164 969  147 911

Consolidated statement of comprehensive income

GroupGroup
Q3 2019    Q3 2018   M9 2019   M9 2018
   EUR ‘000   EUR ‘000   EUR ‘000   EUR ‘000
Revenue  32 382  27 661  98 774  89 505
Cost of goods sold (13 140) (10 909) (38 449) (35 804)
Gross Profit  19 242  16 752  60 325  53 701
Selling expense  (5 335)  (8 534)  (22 356)  (26 715)
Administrative expense  (6 835)  (5 684)  (20 467)  (17 115)
Other operating income  443  542  1 577  1 947
Other operating expense  (558)  (656) (1 262) (2 460)
Share of profit of an associate  (11)  8  92  83
Financial income  251  18  2 093  57
Financial expense  (215)  (703)  (703)  (1 794)
Profit Before Tax  6 982  1 743  19 299  7 704
Corporate income tax  (28)  (73)  (100)  (250)
Deferred corporate income tax  –  (2)  (1)  –
PROFIT FOR THE REPORTING PERIOD  6 954  1 668  19 198  7 454
Other comprehensive income for the reporting period  54  (119)  271  (83)
Total comprehensive income for the reporting period  7 008  1 549  19 469  7 371
Total comprehensive income attributable to:
The equity holders of the Parent Company  7 008  1 549  19 469  7 371
Non-controlling interests  –  –  –  –
Basic and diluted earnings per share, EUR  0.49  0.12  1.36  0.53

JSC Olainfarm is one of the biggest pharmaceutical companies in Latvia with more than 45 years of experience in production of medication and chemical and pharmaceutical products. A basic principle of company’s operations is to produce reliable and effective top -quality products for Latvia and the rest of the world. Products made by the Group are being exported to more than 60 countries of the world, including the Baltics, Russia, other CIS, Europe, Asia, North America and Australia.

 

Additional information:   
Jānis Dubrovskis
Investor Relations Advisor of JSC Olainfarm
Phone: +371 29178878
Email: janis.dubrovskis@olainfarm.com

read more
Groups 9 months profit increased by 158% and exceeds 19 million EUR; active work has begun on renewal of drug dossiers

A new senior executive appointed for Olainfarm with international experience in pharmacy

on November 28, 2019

In accordance with the plan of JSC Olainfarm Supervisory Council to further strengthen the management team of the company, Jeroen Weites has been appointed as Chairman of the Management Board, CEO of Olainfarm Group, with 20 years of international experience in the pharmaceutical industry. The former CEO Lauris Macijevskis will remain on the Board of Olainfarm.

Chairman of the Board, CEO of JSC Olainfarm Group Jeroen Weites is entrusted with the overall management and strategic development of the Olainfarm Group as well as new market niche and sales market expansion.

Gundars Bērziņš, Chairman of the Supervisory Council of JSC Olainfarm, emphasizes: “We are pleased that management team is joined by such an experienced senior executive with considerable expertise in big pharma management, ensuring the companies’ chosen direction of transformation and the growth of business operating income. Europe is one of the markets where JSC Olainfarm wants to grow, while maintaining a solid position in strategically important CIS markets. I am convinced that the addition of such an experienced executive offers real opportunities for the company to develop to a new level. We greatly appreciate the contribution of the current management board under the leadership of L. Macijevskis at such a vital stage for the company and we are delighted he remains on the board. As we move forward, we intend to continue strengthening our management team.”

Chairman of the Board, CEO of JSC Olainfarm Group Jeroen Weites says: “I am delighted to have the opportunity to use my experience in business operations in Europe, CIS and Asia, when joining the Olainfarm team in such a vital stage of development. I have familiarized myself with Olainfarm’s historical success, product portfolios and performance figures, which are all impressive and we must not settle here. Olainfarm has the opportunity to not only become a success story in Latvia but in all the Baltics, where the contribution of every single employee plays a significant role.”

Under the leadership of J. Weites, more than 30 new pharmaceutical products have been successfully introduced in international markets. Jeroen Weites has been the General Manager of Global Healthcare in Sanofi, Bulgaria since 2014, and has led Sanofi’s

General Medicine South Europe (200 mio euro profit) and North Europe (165 mio euro profit) clusters, where his key task was to ensure successful transformation processes for the company. Between 2010 and 2014, he held the position of Senior Director at Sanofi Genzyme, France, primarily responsible for implementing, managing and advising on new European markets as well as developing launch strategies in Japan and China. He also previously held senior positions at UCB Pharma Brussels in Brussels, Belgium and at Biogen Idec in Boston, USA. Weites holds a Master’s degree in Economics from the University of Amsterdam.

Jeroen Weites does not own any shares at the JSC Olainfarm.

Lauris Macijevskis, Raimonds Terentjevs, Signe Baldere-Sildedze, Milana Beļeviča and Mārtiņš Puriņš remain on the Board of the JSC Olainfarm.

 

JSC Olainfarm is one of the largest companies in the Baltic States with more than 45 years of experience in production of pharmaceuticals and chemical and pharmaceutical products. The basic principle of the company is to produce reliable and effective top quality products for Latvia and the whole world. Currently, JSC Olainfarm products are exported to more than 60 countries worldwide, including the Baltic States, Russia, other CIS countries, Europe, North America, Asia and Australia.

 

Additional information: 
Jānis Dubrovskis
Investor Relations Advisor of JSC Olainfarm
Phone: +371 29178878
Email: janis.dubrovskis@olainfarm.com

read more
A new senior executive appointed for Olainfarm with international experience in pharmacy